Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies.

Subjects

Subjects :

Antibodies, Monoclonal, Humanized therapeutic use
Chronic Disease
Humans
Patient Reported Outcome Measures
Nasal Polyps complications
Nasal Polyps drug therapy
Rhinitis drug therapy
Sinusitis drug therapy

Details

Language :

English

ISSN :

1365-2222

Volume :

52

Issue :

2

Database :

MEDLINE

Journal :

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Publication Type :

Academic Journal

Accession number :

35092110

Full Text :

https://doi.org/10.1111/cea.14051